BOSTON – Treating patients with hepatorenal syndrome type 1 for up to 14 days using terlipressin plus albumin rather than albumin alone did not improve the chances of confirmed reversal of...
BOSTON – A 16-week diet and exercise program reduced body weight and portal pressure in a prospective pilot study of 50 obese patients with cirrhosis and portal hypertension.
Twenty-six patients...
BOSTON – Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients.
Terlipressin also seemed...
FROM THE LIVER MEETING 2014A combined formula of ABT-450 with ritonavir, ombitasvir, and dasabuvir, given with ribavirin, yielded high rates of sustained viral response at 12 weeks among...
Viral suppression of hepatitis C virus–infected patients improved neural health as measured by magnetic resonance spectroscopy, according to findings from a new study.
Treatment led to an increase...
Sofosbuvir plus GS-5816 yielded high SVR rates in genotype 3 HCV patientsvitalsKey clinical point: Sofosbuvir plus GS-5816 was well tolerated and achieved high SVR rates among...
BOSTON - A hepatitis C treatment regimen of sofosbuvir and ledipasvir without ribavirin is associated with significant improvement in patient-reported outcomes, new research suggests.<br...
BOSTON – The graying of America will add at least 1 million more patients with chronic hepatitis C virus infection into the Medicare system between 2010 and 2024.
“If all of these patients were...
WASHINGTON – Treatment with nonselective beta-blockers was not associated with an increased mortality risk in patients with decompensated cirrhosis, judging from findings from a retrospective...